Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088856 | 1.00 | TACR1 (0.57) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL3621494 | 1.00 | TACR1 (0.57) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL18394417 | 0.88 | TACR1 (0.63) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL6118975 | 0.85 | TACR1 (0.54) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL2781643 | 0.84 | TACR1 (0.59) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL7965700 | 0.84 | TACR1 (0.59) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL7967707 | 0.84 | TACR1 (0.59) | TACR1TSHRSLC1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL8935783 | 0.82 | TACR1 (0.58) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL903590 | 0.82 | TACR1 (0.73) | TACR1TSHRSLC1A1CA1CA2 | |
| SCHEMBL18579714 | 0.82 | TACR1 (0.73) | TACR1TSHRSLC1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116949003-A | Transaminase mutant and application thereof and enzyme catalysis method | 复旦大学 | 2023-10-27 | — | — | CN | claimed |
| US-5583259-A | FOR RESOLVING RACEMIC MIXTURES | LES LABORATOIRES BEECHAM S.A. (FR) | 1996-12-10 | — | — | US | claimed |
| EP-0570443-B1 | AMINOALCOHOLS USEFUL AS OPTICAL RESOLVING AGENTS | SMITHKLINE BEECHAM LAB (FR) | 1995-11-29 | — | — | EP | claimed |
| EP-0570443-A1 | AMINOALCOHOLS USEFUL AS OPTICAL RESOLVING AGENTS. | BEECHAM LAB SA (FR) | 1993-11-24 | — | — | EP | claimed |
| WO-1992013823-A1 | AMINOALCOHOLS USEFUL AS OPTICAL RESOLVING AGENTS | LES LABORATOIRES BEECHAM S.A. (FR) | 1992-08-20 | — | — | WO | claimed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| CN-116949003-A | Transaminase mutant and application thereof and enzyme catalysis method | 复旦大学 | 2023-10-27 | — | — | CN | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| CN-108368083-B | Heteroaryl compounds and their use as therapeutic agents | 东亚首希控股股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-5583259-A | FOR RESOLVING RACEMIC MIXTURES | LES LABORATOIRES BEECHAM S.A. (FR) | 1996-12-10 | — | — | US | disclosed |
| EP-0570443-B1 | AMINOALCOHOLS USEFUL AS OPTICAL RESOLVING AGENTS | SMITHKLINE BEECHAM LAB (FR) | 1995-11-29 | — | — | EP | disclosed |
| EP-0570443-A1 | AMINOALCOHOLS USEFUL AS OPTICAL RESOLVING AGENTS. | BEECHAM LAB SA (FR) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013823-A1 | AMINOALCOHOLS USEFUL AS OPTICAL RESOLVING AGENTS | LES LABORATOIRES BEECHAM S.A. (FR) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | TACR1 801/4885TSHR 1878/4885SLC1A1 2206/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | TACR1 183/4885TSHR 2257/4885SLC1A1 1671/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | TACR1 801/4885TSHR 1878/4885SLC1A1 2206/4885 |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | TACR1 801/4885TSHR 1878/4885SLC1A1 2206/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | TACR1 801/4885TSHR 1878/4885SLC1A1 2206/4885 |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR1, ACKR3, CXCR1 | TACR1 183/4885TSHR 2257/4885SLC1A1 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.